Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICI35, 868 · 1 trial · 2 indications
The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus \[trapezius squeeze\]) to 5 (Responds readily to name spoken in normal tone \[awake\]). MOAA/S scores were classified as 0-1, 2-4 and 5.
The MOAA/S is a 6-point ordinal scale measuring a patient's level of sedation. Scores range from 0 (No response to painful stimulus \[trapezius squeeze\]) to 5 (Responds readily to name spoken in normal tone \[awake\]). MOAA/S scores were classified as 0-1, 2-4 and 5.
| Arm | Type | Description |
|---|---|---|
| Arm1 - Placebo | PLACEBO_COMPARATOR | - |
| Arm 2 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Arm 3 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Arm 4 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Arm 5 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Arm 6 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Arm 7 - ICI35,868 (propofol) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Infusion of placebo, same infusion rates as for arm 2 |
| ICI35,868 (propofol) | DRUG | Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute |
Inclusion Criteria: * Male or female (females of child bearing potential to confirm not pregnant via test or contraception) * Be undergoing a non-emergent esophagogastroduodenoscopy (EGD) or colonoscopy, including polypectomy that shall be completed within 1 hour Exclusion Criteria: * American So...
ICI35,868 is an investigational small molecule being developed for use in gastrointestinal endoscopy, including procedures such as gastrointestinal polypectomy. It is intended to provide sedation for patients undergoing upper and lower endoscopic tests. The drug is currently in Phase 2 clinical development.
ICI35,868 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical trials for gastrointestinal endoscopy indications.
ICI35,868 is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 clinical trial for the drug has been completed, involving 123 participants.
ICI35,868 has one completed Phase 2 clinical trial registered under NCT01189604. The trial was a dose rate range finding study of propofol for minimal-to-moderate sedation during upper and lower endoscopic tests, conducted in Japan with 123 participants.
ICI35,868 is being studied in a clinical trial that evaluates propofol for sedation during endoscopic procedures. The trial title references propofol, and ICI35,868 may be the investigational name for this drug in the context of this study.